Antibodies against clostridium difficile toxins and uses thereof
Antibodies that specifically bind to toxins of C. difficile , antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
1. A method of treating Clostridium difficile ( C. difficile ) disease in a subject, the method comprising administering to the subject:
(a) an isolated monoclonal antibody that binds to C. difficile toxin A, or an antigen binding portion thereof, wherein the antibody binds to the same epitope of C. difficile toxin A recognized by an antibody comprising a heavy and light chain variable region having the amino acid sequences set forth in SEQ ID NOs: 1 and 4, SEQ ID NOs: 2 and 5, or SEQ ID NOs: 3 and 6, respectively; and
(b) an isolated monoclonal antibody that binds to C. difficile toxin B, or an antigen binding portion thereof, wherein the antibody binds to the same epitope of C. difficile toxin B recognized by an antibody comprising a heavy and light chain variable region having the amino acid sequences set forth in SEQ ID NOs: 54 and 58, respectively,
wherein C. difficile disease is treated in the subject.
2. A method of treating Clostridium difficile ( C. difficile ) disease in a subject, the method comprising administering to the subject:
(a) an isolated monoclonal antibody that binds to C. difficile toxin A, or an antigen binding portion thereof, wherein the antibody is selected from the group consisting of:
(i) an antibody comprising a heavy chain variable region CDR1 comprising SEQ ID NO:7, a heavy chain variable region CDR2 comprising SEQ ID NO:8, a heavy chain variable region CDR3 comprising SEQ ID NO:9, a light chain variable region CDR1 comprising SEQ ID NO:16, a light chain variable region CDR2 comprising SEQ ID NO:17 and a light chain variable region CDR3 comprising SEQ ID NO:18;
(ii) an antibody comprising a heavy chain variable region CDR1 comprising SEQ ID NO:10, a heavy chain variable region CDR2 comprising SEQ ID NO:11, a heavy chain variable region CDR3 comprising SEQ ID NO:12, a light chain variable region CDR1 comprising SEQ ID NO:19, a light chain variable region CDR2 comprising SEQ ID NO:20 and a light chain variable region CDR3 comprising SEQ ID NO:21; and
(iii) an antibody comprising a heavy chain variable region CDR1 comprising SEQ ID NO:13, a heavy chain variable region CDR2 comprising SEQ ID NO:14, a heavy chain variable region CDR3 comprising SEQ ID NO:15, a light chain variable region CDR1 comprising SEQ ID NO:22, a light chain variable region CDR2 comprising SEQ ID NO:23 and a light chain variable region CDR3 comprising SEQ ID NO:24;
and
(b) an isolated monoclonal antibody that binds to C. difficile toxin B, or an antigen binding portion thereof, wherein the antibody comprises a heavy chain variable region CDR1 comprising SEQ ID NO:62, a heavy chain variable region CDR2 comprising SEQ ID NO:64, a heavy chain variable region CDR3 comprising SEQ ID NO:66, a light chain variable region CDR1 comprising SEQ ID NO:68, a light chain variable region CDR2 comprising SEQ ID NO:70 and a light chain variable region CDR3 comprising SEQ ID NO:72,
wherein C. difficile disease is treated in the subject.
3. The method of claim 2 , wherein the isolated monoclonal antibody that binds to C. difficile toxin A, or an antigen binding portion thereof, comprises a heavy chain variable region CDR1 comprising SEQ ID NO:7, a heavy chain variable region CDR2 comprising SEQ ID NO:8, a heavy chain variable region CDR3 comprising SEQ ID NO:9, a light chain variable region CDR1 comprising SEQ ID NO:16, a light chain variable region CDR2 comprising SEQ ID NO:17 and a light chain variable region CDR3 comprising SEQ ID NO:18.
4. The method of claim 2 , wherein the isolated monoclonal antibody that binds to C. difficile toxin A, or an antigen binding portion thereof, comprises a heavy chain variable region CDR1 comprising SEQ ID NO:10, a heavy chain variable region CDR2 comprising SEQ ID NO:11, a heavy chain variable region CDR3 comprising SEQ ID NO:12, a light chain variable region CDR1 comprising SEQ ID NO:19, a light chain variable region CDR2 comprising SEQ ID NO:20 and a light chain variable region CDR3 comprising SEQ ID NO:21.
5. The method of claim 2 , wherein the isolated monoclonal antibody that binds to C. difficile toxin A, or an antigen binding portion thereof, comprises a heavy chain variable region CDR1 comprising SEQ ID NO:13, a heavy chain variable region CDR2 comprising SEQ ID NO:14, a heavy chain variable region CDR3 comprising SEQ ID NO:15, a light chain variable region CDR1 comprising SEQ ID NO:22, a light chain variable region CDR2 comprising SEQ ID NO:23 and a light chain variable region CDR3 comprising SEQ ID NO:24.
6. The method of claim 2 , wherein the method comprises administering to the subject:
(a) an isolated monoclonal antibody that binds to C. difficile toxin A, or an antigen binding portion thereof, wherein the antibody comprises a heavy and light chain variable region having the amino acid sequences set forth in SEQ ID NOs: 1 and 4, SEQ ID NOs: 2 and 5, or SEQ ID NOs: 3 and 6, respectively; and
(b) an isolated monoclonal antibody that binds to C. difficile toxin B, or an antigen binding portion thereof, wherein the antibody comprises a heavy and light chain variable region having the amino acid sequences set forth in SEQ ID NOs: 54 and 58, respectively,
wherein C. difficile disease is treated in the subject.
7. The method of claim 6 , wherein the isolated monoclonal antibody that binds to C. difficile toxin A, or an antigen binding portion thereof, comprises heavy and light chain variable regions having the amino acid sequences set forth in SEQ ID NOs: 1 and 4, respectively.
8. The method of claim 6 , wherein the isolated monoclonal antibody that binds to C. difficile toxin A, or an antigen binding portion thereof, comprises heavy and light chain variable regions having the amino acid sequences set forth in SEQ ID NOs: 2 and 5, respectively.
9. The method of claim 6 , wherein the isolated monoclonal antibody that binds to C. difficile toxin A, or an antigen binding portion thereof, comprises heavy and light chain variable regions having the amino acid sequences set forth in SEQ ID NOs: 3 and 6, respectively.
10. The method of claim 1 , wherein the antibodies, or antigen binding portions thereof, are administered separately.
11. The method of claim 1 , wherein the antibodies, or antigen binding portions thereof, are administered together.
12. The method of claim 1 , wherein the subject is human.
13. The method of claim 1 , wherein the antibodies, or antigen binding portions thereof, are administered intravenously, intramuscularly, or subcutaneously to the subject.
14. The method of claim 1 , wherein the C. difficile disease is antibiotic-associated diarrhea, C. difficile -mediated pseudomembranous colitis (PMC), diarrhea, or relapse of C. difficile -mediated disease.
15. The method of claim 1 , wherein the antibodies, or antigen binding portions thereof, are administered in combination with an antibiotic or C. difficile vaccine.
16. The method of claim 15 , wherein the antibiotic is vancomycin or metronidazole.
17. The method of claim 2 , wherein the antibodies, or antigen binding portions thereof, are administered separately.
18. The method of claim 2 , wherein the antibodies, or antigen binding portions thereof, are administered together.
19. The method of claim 2 , wherein the subject is human.
20. The method of claim 2 , wherein the antibodies, or antigen binding portions thereof, are administered intravenously, intramuscularly, or subcutaneously to the subject.
21. The method of claim 2 , wherein the C. difficile disease is antibiotic-associated diarrhea, C. difficile -mediated pseudomembranous colitis (PMC), diarrhea, or relapse of C. difficile -mediated disease.
22. The method of claim 2 , wherein the antibodies, or antigen binding portions thereof, are administered in combination with an antibiotic or C. difficile vaccine.
23. The method of claim 22 , wherein the antibiotic is vancomycin or metronidazole.
24. The method of claim 6 , wherein the antibodies, or antigen binding portions thereof, are administered separately.
25. The method of claim 6 , wherein the antibodies, or antigen binding portions thereof, are administered together.
26. The method of claim 6 , wherein the subject is human.
27. The method of claim 6 , wherein the antibodies, or antigen binding portions thereof, are administered intravenously, intramuscularly, or subcutaneously to the subject.
28. The method of claim 6 , wherein the C. difficile disease is antibiotic-associated diarrhea, C. difficile -mediated pseudomembranous colitis (PMC), diarrhea, or relapse of C. difficile -mediated disease.
29. The method of claim 6 , wherein the antibodies, or antigen binding portions thereof, are administered in combination with an antibiotic or C. difficile vaccine.
30. The method of claim 29 , wherein the antibiotic is vancomycin or metronidazole.